Hospital
Hca Healthone LLC
Hca Healthone LLC was paid $19.64M by Medicaid between Jan 2018 and Dec 2024, across 81 billing codes. Its largest line is 99283, emergency room visit (moderate) — 45% of everything it billed.
33Billing provider infoHCA HEALTHONE LLC
ENGLEWOOD, CO 80113
ENGLEWOOD, CO 80113
33aNPI1396790200assigned 05/23/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$19.64M
24GClaims483,996
24DCodes billed81
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Colorado
Rank by total paid#10 of 51
Median peer was paid$1.24M
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 80,478 | $3.35M | |
| 2019 | 82,639 | $3.27M | |
| 2020 | 61,997 | $2.42M | |
| 2021 | 65,580 | $2.50M | |
| 2022 | 66,215 | $2.99M | |
| 2023 | 67,443 | $2.81M | |
| 2024incomplete | 59,644 | $2.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 45% | 76,189 | 69,279 | $8.75M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 38% | 74,903 | 66,509 | $7.38M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.7% | 5,820 | 5,174 | $1.33M |
| 80053 | Comprehensive metabolic panel | 3.3% | 45,457 | 40,333 | $653K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 5,793 | 5,286 | $571K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 14,373 | 12,581 | $272K |
| 84484 | <1% | 9,697 | 7,064 | $175K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,932 | 1,719 | $121K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 597 | 536 | $93K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 323 | 290 | $59K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 798 | 666 | $39K |
| 80320 | <1% | 339 | 276 | $31K |
69 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,965 | $28K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 43 | $25K |
| 99285 | Emergency room visit (most serious) | <1% | 273 | $24K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 174 | $18K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 43,694 | $10K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 139 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 29 | $7K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,040 | $7K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 64 | $7K |
| G0378 | Hospital observation service, per hour | <1% | 181 | $6K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 24 | $5K |
| 17250 | <1% | 60 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 21,015 | $4K |
| 73130 | <1% | 33 | $3K | |
| 85027 | <1% | 68,958 | $3K | |
| 83690 | <1% | 17,829 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 16 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,590 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 830 | $2K |
| 97165 | <1% | 27 | $2K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 18,534 | $2K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,194 | $858.56 |
| 85379 | <1% | 42 | $729.88 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 14 | $635.88 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,754 | $632.08 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,359 | $549.46 |
| 83605 | <1% | 27 | $517.73 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,703 | $515.11 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,288 | $337.03 |
| 82077 | <1% | 565 | $311.63 | |
| 97799 | <1% | 26 | $281.14 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 13 | $263.82 |
| 81001 | <1% | 7,663 | $228.15 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 93 | $214.92 |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 334 | $139.58 |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 262 | $126.50 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 478 | $124.66 |
| 84703 | <1% | 11,941 | $119.79 | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 406 | $102.84 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 13 | $91.40 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 161 | $63.18 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,384 | $58.55 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 176 | $6.08 |
| 81003 | <1% | 3,809 | $4.94 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,428 | $3.99 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 116 | $0.63 |
| 81025 | 0% | 87 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 2,995 | $0.00 |
| 73610 | 0% | 14 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 148 | $0.00 |
| 82075 | 0% | 180 | $0.00 | |
| 99203 | Doctor's office visit, new patient (routine) | 0% | 68 | $0.00 |
| 97161 | 0% | 15 | $0.00 | |
| 87420 | 0% | 38 | $0.00 | |
| 84100 | 0% | 15 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 16 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 42 | $0.00 |
| 87081 | 0% | 135 | $0.00 | |
| 99213 | Doctor's office visit, returning patient (routine) | 0% | 330 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 559 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 87 | $0.00 |
| 87430 | 0% | 108 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 15 | $0.00 |
| 83735 | 0% | 17 | $0.00 | |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 28 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 28 | $0.00 |
| 96376 | 0% | 15 | $0.00 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 39 | $0.00 |
| 80047 | 0% | 29 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGIBBS, JAMIE (CFO)
| Provider | Location | Paid |
|---|---|---|
| Awareness Collaborative | Broomfield, CO | $543K |
| Awareness Collaborative PLLC | Broomfield, CO | $6K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.